| In heart failure, chronic, systolic (reduced ejection fraction) |
The Use of
cardiac glycosides, digitoxin As Treatment, Chronic |
Is better Than
placebo |
To reduce at 1.5 years the combined risk of hospitalization for heart failure: (28% digitoxin VS 30% placebo) or death (27% digitoxin VS 29.5% placebo) |
|
||
| Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | ||
| DIGIT-HF Study Group; Bavendiek U, Großhennig A, Schwab J, Berliner D, Rieth A, Maier LS, Gaspar T, Thomas NH, Liu X, Schallhorn S, Angelini E, Soltani S, Rathje F, Sandu MA, Geller W, Hambrecht R, Zdravkovic M, Philipp S, Kosevic D, Nickenig G, Scheiber D, Winkler S, Becher PM, Lurz P, Hülsmann M, Wiesner S, Schröder C, Neuhaus B, Seltmann A, von der Leyen H, Veltmann C, Störk S, Böhm M, Koch A, Bauersachs J | ||
| Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany | ||
| Randomized Controlled Trial, Multicenter Study | ||
| Background: The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. Methods: In this international, double-blind, placebo-controlled trial, we randomly assigned patients with chronic heart failure who had a left ventricular ejection fraction of 40% or less and a New York Heart Association (NYHA) functional class of III or IV or a left ventricular ejection fraction of 30% or less and an NYHA functional class of II in a 1:1 ratio to receive digitoxin (at a starting dose of 0.07 mg once daily) or matching placebo in addition to guideline-directed medical therapy. The primary outcome was a composite of death from any cause or hospital admission for worsening heart failure, whichever occurred first. Results: Among 1240 patients who underwent randomization, 1212 fulfilled the criteria for inclusion in the modified intention-to-treat population: 613 patients in the digitoxin group and 599 in the placebo group. Over a median follow-up of 36 months, a primary-outcome event occurred in 242 patients (39.5%) in the digitoxin group and 264 (44.1%) in the placebo group (hazard ratio for death or first hospital admission for worsening heart failure, 0.82; 95% confidence interval [CI], 0.69 to 0.98; P = 0.03). Death from any cause occurred in 167 patients (27.2%) in the digitoxin group and 177 (29.5%) in the placebo group (hazard ratio, 0.86; 95% CI, 0.69 to 1.07). A first hospital admission for worsening heart failure occurred in 172 patients (28.1%) in the digitoxin group and 182 (30.4%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.69 to 1.05). At least one serious adverse event occurred in 29 patients (4.7%) in the digitoxin group and 17 (2.8%) in the placebo group. Conclusions: Treatment with digitoxin led to a lower combined risk of death from any cause or hospital admission for worsening heart failure than placebo among patients with heart failure and reduced ejection fraction who received guideline-directed medical therapy. Funded by the German Federal Ministry of Research, Technology, and Space and others; DIGIT-HF EudraCT number, 2013-005326-38. |
||
| Pubmed record: PMID: 40879434 | ||
| Notes: 0 | ||
| Theme: 0 |